Verastem (NASDAQ:VSTM) CEO Sells $12,470.40 in Stock

November 6, 2026 by InsiderTrades.com

Key Points

CEO Dan Paterson sold 1,299 shares for $12,470.40 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 0.20%; he retained 651,413 shares.
Verastem’s quarterly results missed expectations: reported EPS was -$0.74 versus the -$0.47 consensus, while revenue of $24.01 million was below estimates of $26.57 million.
Analysts’ consensus rating is Moderate Buy, with an average price target of $16.67.

Verastem, Inc. (NASDAQ:VSTM - Get Free Report) CEO Dan Paterson sold 1,299 shares of the business's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $9.60, for a total transaction of $12,470.40. Following the completion of the transaction, the chief executive officer owned 651,413 shares of the company's stock, valued at $6,253,564.80. This trade represents a 0.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dan Paterson also recently made the following trade(s):

On Thursday, October 1st, Dan Paterson sold 44,121 shares of Verastem stock. The stock was sold at an average price of $8.00, for a total value of $352,968.00.

Verastem Stock Down 4.8%

Shares of VSTM opened at $9.38 on Friday. The firm has a market capitalization of $849.45 million, a price-to-earnings ratio of -3.53 and a beta of 0.45. The company has a debt-to-equity ratio of 1.48, a quick ratio of 2.22 and a current ratio of 2.25. The business's fifty day moving average price is $8.36 and its two-hundred day moving average price is $6.24. Verastem, Inc. has a 52 week low of $3.43 and a 52 week high of $10.82.

Verastem (NASDAQ:VSTM - Get Free Report) last released its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.27). The firm had revenue of $24.01 million during the quarter, compared to analyst estimates of $26.57 million. Verastem had a negative net margin of 231.59% and a negative return on equity of 467.49%. On average, analysts predict that Verastem, Inc. will post -1.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

VSTM has been the subject of several recent research reports. Wall Street Zen raised Verastem from a "sell" rating to a "hold" rating in a report on Sunday, September 27th. Benchmark reaffirmed a "buy" rating on shares of Verastem in a research note on Friday, October 16th. BTIG Research raised their target price on shares of Verastem from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Thursday, October 15th. Weiss Ratings cut shares of Verastem from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, October 15th. Finally, Wolfe Research began coverage on shares of Verastem in a research note on Thursday, September 17th. They set an "outperform" rating for the company. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Verastem has a consensus rating of "Moderate Buy" and an average price target of $16.67.

Check Out Our Latest Research Report on Verastem

Verastem News Summary

Here are the key news stories impacting Verastem this week:

Positive Sentiment: Verastem’s reported quarterly loss improved from $1.35 per share a year ago, though it remained larger than analysts expected. Zacks report
Neutral Sentiment: CEO Dan Paterson sold 1,299 shares—about 0.20% of his holdings—in a transaction under a pre-arranged Rule 10b5-1 plan, leaving him with more than 651,000 shares. The small, scheduled sale may have limited significance for investors. SEC filing
Neutral Sentiment: The company posted an updated corporate presentation on its oncology programs, but the report provided no specific new developments likely to change the investment outlook. Corporate presentation update
Negative Sentiment: Third-quarter adjusted loss was $0.72 per share, wider than the $0.47-per-share consensus estimate. Revenue of $24.0 million also fell short of expectations of about $26.6 million. The earnings and sales misses are the clearest near-term headwinds for the stock. Third-quarter results

Hedge Funds Weigh In On Verastem

Several institutional investors have recently modified their holdings of VSTM. AIGH Capital Management LLC bought a new stake in shares of Verastem in the 1st quarter valued at about $10,600,000. Opaleye Management Inc. acquired a new stake in shares of Verastem in the 2nd quarter valued at approximately $6,876,000. Exome Asset Management LLC boosted its stake in Verastem by 58.5% during the 1st quarter. Exome Asset Management LLC now owns 636,700 shares of the biopharmaceutical company's stock worth $3,375,000 after acquiring an additional 234,957 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in Verastem by 157.2% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 569,195 shares of the biopharmaceutical company's stock worth $2,174,000 after acquiring an additional 347,872 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in Verastem by 31.6% during the 1st quarter. Bank of America Corp DE now owns 416,985 shares of the biopharmaceutical company's stock worth $2,210,000 after acquiring an additional 100,123 shares during the last quarter. 88.37% of the stock is currently owned by institutional investors and hedge funds.

Verastem Company Profile

(Get Free Report)

Verastem, operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing targeted therapies for cancer. The company's research is centered on tumors driven by abnormalities in the RAS/MAPK signaling pathway, which can promote cancer-cell growth and resistance to treatment.

Verastem's leading product candidates include avutometinib, an oral RAF/MEK clamp designed to inhibit signaling within the RAS/MAPK pathway, and defactinib, an oral focal adhesion kinase inhibitor.